The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
-
Published:2023-08-31
Issue:17
Volume:24
Page:13558
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Liang Xuan-Bing1,
Dai Zhi-Cheng1,
Zou Rong1,
Tang Ji-Xin1ORCID,
Yao Cui-Wei1
Affiliation:
1. Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Diseases of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China
Abstract
Inflammation is a crucial pathological feature in cancers and kidney diseases, playing a significant role in disease progression. Cyclin-dependent kinases CDK4 and CDK6 not only contribute to cell cycle progression but also participate in cell metabolism, immunogenicity and anti-tumor immune responses. Recently, CDK4/6 inhibitors have gained approval for investigational treatment of breast cancer and various other tumors. Kidney diseases and cancers commonly exhibit characteristic pathological features, such as the involvement of inflammatory cells and persistent chronic inflammation. Remarkably, CDK4/6 inhibitors have demonstrated impressive efficacy in treating non-cancerous conditions, including certain kidney diseases. Current studies have identified the renoprotective effect of CDK4/6 inhibitors, presenting a novel idea and potential direction for treating kidney diseases in the future. In this review, we briefly reviewed the cell cycle in mammals and the role of CDK4/6 in regulating it. We then provided an introduction to CDK4/6 inhibitors and their use in cancer treatment. Additionally, we emphasized the importance of these inhibitors in the treatment of kidney diseases. Collectively, growing evidence demonstrates that targeting CDK4 and CDK6 through CDK4/6 inhibitors might have therapeutic benefits in various cancers and kidney diseases and should be further explored in the future.
Funder
Natural Science Foundation of Guangdong Province
Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases
Discipline Construction Project of Guangdong Medical University
Zhanjiang City Science and Technology Development Special Funds Competitive Allocation Project
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference151 articles.
1. Third-CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib;Poratti;Eur. J. Med. Chem.,2019
2. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer;Beaver;Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.,2015
3. Ribociclib: First Global Approval;Syed;Drugs,2017
4. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors;Patnaik;Cancer Discov.,2016
5. The cell cycle in stem cell proliferation, pluripotency and differentiation;Liu;Nat. Cell Biol.,2019